ReviewTransgenic research1999
Internal ribosome entry sites (IRESs): reality and use.
Review in Transgenic research, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform.Scientific reports · 2023Article
- Vector design for enhancing expression level and assembly of knob-into-hole based FabscFv-Fc bispecific antibodies in CHO cells.Antibody therapeutics · 2022Article
- Stable, high yield expression of gp145 Env glycoprotein from HIV-1 in mammalian cells.Biologicals : journal of the International Association of Biological Standardization · 2021Article
- Intestinal Neurod1 expression impairs paneth cell differentiation and promotes enteroendocrine lineage specification.Scientific reports · 2019Article
- The Cyclin-Dependent Kinase 5 Inhibitor Peptide Inhibits Herpes Simplex Virus Type 1 Replication.Scientific reports · 2019Article
- Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth.Scientific reports · 2017Article
- TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice.Nature communications · 2017Article
- Production of heterozygous alpha 1,3-galactosyltransferase (GGTA1) knock-out transgenic miniature pigs expressing human CD39.Transgenic research · 2017Article
- Rescued Chondrogenesis of Mesenchymal Stem Cells under Interleukin 1 Challenge by Foamyviral Interleukin 1 Receptor Antagonist Gene Transfer.Frontiers in pharmacology · 2017Article
- Vectorology and factor delivery in induced pluripotent stem cell reprogramming.Stem cells and development · 2014Review
- Somatostatin receptor type 2-based reporter expression after plasmid-based in vivo gene delivery to non-small cell lung cancer.Molecular imaging · 2013Article
- Comparison of internal ribosome entry site (IRES) and Furin-2A (F2A) for monoclonal antibody expression level and quality in CHO cells.PloS one · 2013Article
- Improvement of reporter activity by IRES-mediated polycistronic reporter system.Nucleic acids research · 2008Article
- Sustained analgesic peptide secretion and cell labeling using a novel genetic modification.Cell transplantation · 2008Article
- Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas.Cancer gene therapy · 2007Article
- In situ analysis of Raidd-beta-galactosidase fusion gene expression in transgenic mouse midgestation embryos.Transgenic research · 2005Article
- Genetic targeting of cerebellar Purkinje cells: history, current status and novel strategies.Cerebellum (London, England) · 2002Review
- Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation.Molecular and cellular biology · 2001Article
- Transgenic animal bioreactors.Transgenic research · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IRESs are known to recruit ribosomes directly, without a previous scanning of untranslated region of mRNA by the ribosomes. IRESs have been found in a number of viral and cellular mRNAs. Experimentally, IRESs are commonly used to direct the expression of the second cistrons of bicistronic mRNAs. The mechanism of action of IRESs is not fully understood and a certain number of laboratories were not successful in using them in a reliable manner. Three observations done in our laboratory suggested that IRESs might not work as functionally as it was generally believed. Stem loops added before IRESs inhibited mRNA translation. When added into bicistronic mRNAs, IRESs initiated translation of the second cistrons efficiently only when the intercistronic region contained about 80 nucleotides, and they did not work any more effectively with intercistronic regions containing at least 300-400 nucleotides. Conversely, IRESs inserted at any position into the coding region of a cistron interrupted its translation and initiated translation of the following cistron. The first two data are hardly compatible with the idea that IRESs are able to recruit ribosomes without using the classical scanning mechanism. IRESs are highly structured and cannot be scanned by the 40S ribosomal subunit. We suggest that IRESs are short-circuited and are essentially potent stimulators favoring translation in particular physiological situations.
Indexed as
Identifiers
10478488What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.